National Cancer Institute

Business Services · Maryland, United States · 3,500 Employees

NCI is attempting to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers.Read More

Contact

Who is National Cancer Institute

Headquarters

9609 Medical Center Dr Rm 3e528, Rockville, Maryland, 20850, United States

Phone Number

(301) 496-4345

Website

www.cancer.gov

Revenue

$739.7M

Industry

Medical Testing & Clinical Laboratories

Healthcare

Is this data correct?

View contact profiles from National Cancer Institute

Top Competitors of National Cancer Institute

Dana-Farber Cancer Institute
4,355
$1.4B
1
City of Hope
6,000
$2.5B
2
Roswell Park Comprehensive Can...
3,935
$895.5M
3
Fox Chase Cancer Center
2,506
$358.8M
4
Moffitt Cancer Center
7,500
$1.1B
5
Fred Hutchinson Cancer Researc...
5,700
$984M
6

National Cancer Institute Org Chart

Phone

Timothy Harris

Chief Technology Officer

Phone

Jeff Shilling

Chief Information Officer

Phone

View Email Formats for National Cancer Institute

National Cancer Institute Company Metrics

Company Insights

Employee Growth Rate

Acquisitions & Subsidiaries

Jul 18, 2022

Environmental Health Perspectives

Jul 18, 2022

NIH CIO-SP3 Support Center

Jul 18, 2022

Inhalants

Jul 18, 2022

Physiome

Jul 18, 2022

PubMed Central

Jul 18, 2022

Heart Truth

See More Acquisitions & Subsidiaries

National Cancer Institute Tech Stack

G2Crowd

FedEx

Microsoft OneNote

Microsoft

React

Facebook

See more technologies

National Cancer Institute News & Media

Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS® T-cell receptor platform. MSLN is a cell-surface protein overexpressed in many s
Mar 14, 2023
www.businesswire.com
Cancer Research Initiative Announces Funding for Global Research Community to Take on Nine of Cancer’s Toughest Challenges
WASHINGTON--(BUSINESS WIRE)--Cancer Grand Challenges, a research initiative co-founded by Cancer Research UK and the National Cancer Institute (NCI), today announced nine new challenges for the global research community to take on – representing obstacles that continue to impede progress against cancer and, ultimately, benefits for patients. Cancer Grand Challenges unites the world's brightest minds across boundaries and disciplines to tackle cancer's most complex challenges. In support of Canc
Mar 8, 2023
www.businesswire.com
ENHERTU® Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZeneca’s ENHERTU® (trastuzumab deruxtecan) met the pre-specified target for objective response rate (ORR) and demonstrated durable response across multiple HER2 expressing advanced solid tumors in heavily pre-treated patients. ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being joi
Mar 6, 2023
www.businesswire.com
Chubb Launches First-Of-Its-Kind Personalized Genetics-Based Cancer Program
Brings Advanced Cancer Risk Identification to Mainstream America, Coupled with Treatment, Recovery and Insurance Protection WHITEHOUSE STATION, N.J., Feb. 22, 2023 /PRNewswire/ -- Chubb Workplace Benefits (CWB), a Chubb business that partners with benefits brokers and consultants to offer...
Feb 22, 2023
www.prnewswire.com
City of Hope Comprehensive Cancer Center earns highest ranking from National Cancer Institute
$23 million also awarded for research, training and community outreach City of Hope has held the prestigious NCI designation since 1981 LOS ANGELES, Feb. 16, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, announced...
Feb 16, 2023
www.prnewswire.com